Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beta-hCG + EryThropoietin in Acute Stroke

Trial Profile

Beta-hCG + EryThropoietin in Acute Stroke

Phase of Trial: Phase II

Latest Information Update: 15 May 2009

At a glance

  • Drugs NTx 265 (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms BETAS-b
  • Sponsors Trillium Therapeutics Inc
  • Most Recent Events

    • 15 May 2009 Stem Cell Therapeutics announced that the U.S. FDA has issued a formal letter confirming immediate removal of the clinical hold placed on the Phase IIb stroke trial.
    • 18 Sep 2008 Stem Cell Therapeutics has received a verbal request (from the US FDA) not to begin trial recruitment yet as data from an unrelated foreign study have highlighted safety concerns associated with epoetin-alfa.
    • 11 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top